大肉签首日暴涨92%！7月创新药新股被疯抢，港股IPO持续火爆 原创 阅读全文 格隆汇新股 ...

"由于港股IPO审核周期短，对于国内投资机构来说，也就多了一个高效率的退出渠道。我们也鼓励那 些短期内无法完成A股IPO的项目公司去香港IPO。"一位股权投资机构的人士对第一财经称。 也有多位投行人士告诉记者，此轮港股IPO热潮主要由多重因素共同驱动，包括港股估值修复预期与流 动性改善、政策支持与上市制度优化、中概股回归与二次上市需求持续等，已调配资源，加大港股IPO 项目挖掘力度，积极参与港股IPO市场。 MACD金叉信号形成，这些股涨势不错！ 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 【#赴港上市持续火热#，#6月来8家企业A股IPO未果后转道港股#】赴港上市热之下，一些在A股市场 撤否的拟IPO企业，转战港股IPO；也有多数A股上市公司积极筹备港股上市事宜。 据不完全统计，自6月以来，有8家企业在A股IPO未果后转道港股。A股上市公司寻求在港股二次上市 方面，根据Wind数据，今年以来至7月30日，已有10家A股上市公司在港股上市。另外，还有多数A股 上市公司正在加快赴港上市步伐。 责任编辑：常福强 ...

今年1月，大行科工首度向港交所递表时，其"大手笔"的分红就曾引发外界关注。不过，此次大行科工 递交的招股书中显示，今年4月，大行科工再度大手笔分红，报告期内已累计达6000万元，其中大部分 流向公司创始人、实控人、持股近90%的控股股东韩德玮。而与此同时，除自有工厂产能始终无法得到 补充外，大行科工还自曝从2022年至今欠缴员工社保660万元。 就上述问题，南都湾财社记者近日多次联系大行科工相关负责人并发送采访函，但截至目前未收到回 复。 业绩数据"突飞猛进" 六成产能靠代工"顽疾"仍在 时隔约半年，大行科工再度向IPO发起冲刺。 近日，港股IPO板块披露了大行科工最新提交的招股书。这已是这家折叠自行车"龙头"年内第二次递 表。根据证监会国际合作司发布的大行科工上市备案通知书，大行科工拟发行不超过910万股境外普通 股。 根据招股书，其旗下的主要产品为折叠自行车。业绩方面，大行科工2022年-2024年及2025年前四个月 的营业收入分别为2.54亿元、3亿元、4.51亿元和1.85亿元，净利润分别约为3143.4万元、3485万元、 5229.9万元和2152.8万元。 由此计算，大行科工近年来业绩增长可谓 ...

近日，江苏中慧元通生物科技股份有限公司通过港交所聆讯。该公司曾计划在科创板上市，之后转战港 股。 赴港上市热之下，一些在A股市场撤否的拟IPO企业，转战港股IPO；也有多数A股上市公司积极筹备港 股上市事宜。 据不完全统计，自6月以来，有8家企业在A股IPO未果后转道港股。A股上市公司寻求在港股二次上市 方面，根据Wind数据，今年以来至7月30日，已有10家A股上市公司在港股上市。另外，还有多数A股 上市公司正在加快赴港上市步伐。 "由于港股IPO审核周期短，对于国内投资机构来说，也就多了一个高效率的退出渠道。我们也鼓励那 些短期内无法完成A股IPO的项目公司去香港IPO。"一位股权投资机构的人士对第一财经称。 也有多位投行人士告诉记者，此轮港股IPO热潮主要由多重因素共同驱动，包括港股估值修复预期与流 动性改善、政策支持与上市制度优化、中概股回归与二次上市需求持续等，已调配资源，加大港股IPO 项目挖掘力度，积极参与港股IPO市场。 赴港上市持续火热 6月以来，有多家企业在A股IPO未果后转战港股，并有了新进展。 还有些公司则在筹备阶段。7月25日晚间，首创证券（601136.SH）官宣赴港上市计划，拟发 ...

Core Viewpoint - Dahon Technology (Shenzhen) Co., Ltd. is planning to issue up to 9.1 million shares for overseas listing on the Hong Kong Stock Exchange, with the funds aimed at modernizing production systems, expanding operations, enhancing distribution networks, and strengthening R&D capabilities [1][2]. Financial Performance - Dahon Technology has shown impressive financial growth, with revenues increasing from 254 million yuan in 2022 to an expected 451 million yuan in 2024, representing a compound annual growth rate (CAGR) of 33.1% [3]. - The net profit for the same period is projected to rise from 31.43 million yuan in 2022 to 52.30 million yuan in 2024 [3]. - In the first four months of 2025, the company achieved revenue of 185 million yuan, a year-on-year increase of 46.91%, and a net profit of 21.53 million yuan, up 69.11% [5]. Business Model Concerns - Dahon Technology's sales heavily rely on third-party distributors, contributing 61.3% to 70.5% of total revenue from 2022 to 2025, with a low gross margin of 26.9% in early 2025 [6]. - The company's inventory has been rising, with a balance of 150 million yuan by April 2025, accounting for 40.7% of total assets, indicating significant liquidity strain [6]. - Inventory turnover days were high, averaging around 118 days from 2022 to 2024, compared to competitors like Shanghai Phoenix, which had much lower turnover days [6]. Production Dependency - Dahon Technology primarily relies on OEM suppliers for production, with internal production from its Huizhou factory declining from 70.79% of total sales in 2022 to 37.18% in early 2025 [7]. - The company has increasingly depended on a few major suppliers, with procurement from the top five suppliers rising from 32.7% in 2022 to 52.1% in early 2025 [8]. Governance Issues - The founder, Han Dewei, controls 90.16% of the company, raising concerns about governance and potential conflicts of interest, especially following significant dividend payouts that have largely benefited him [2][11]. - Dahon Technology has faced scrutiny over its high dividend payouts, which have totaled 61.5 million yuan since 2022, with a significant portion going to Han Dewei [13][14]. Market Position - Dahon Technology is a leading player in the folding bicycle market, holding a 26.3% market share by retail volume and a 36.5% share by retail value in mainland China as of 2024 [3].

Summary of Key Points Core Viewpoint - The Hong Kong Stock Exchange reported that during the week of July 21 to July 27, a total of 9 companies submitted applications, 1 company passed the hearing, and 1 new stock was listed. Company Summaries - **GoerTek Inc.**: Submitted an application on July 21, focusing on smart sensing interaction solutions, particularly acoustic sensors. It is the fifth largest global provider in this sector with a market share of 2.2% and the largest in China. Revenue for 2022 to 2024 was approximately RMB 31.21 billion, RMB 30.01 billion, and RMB 45.36 billion respectively, with net profits of RMB 3.26 billion, RMB 2.89 billion, and RMB 3.09 billion [2][2]. - **Guangdong Tianyu Semiconductor Co., Ltd.**: Submitted an application on July 22, specializing in silicon carbide epitaxial wafers. It holds the top position in China's market with a revenue market share of 30.6%. Revenue for 2022 to 2024 was approximately RMB 4.37 billion, RMB 11.71 billion, and RMB 5.2 billion respectively, with net profits of RMB 281.4 million, RMB 95.88 million, and a loss of RMB 500 million [3][3]. - **Daheng Technology (Shenzhen) Co., Ltd.**: Submitted an application on July 22, known for its folding bicycles, holding a market share of 26.3% in volume and 36.5% in revenue in China. Revenue for 2022 to 2024 was approximately RMB 2.54 billion, RMB 3 billion, and RMB 4.51 billion respectively, with net profits of RMB 314.34 million, RMB 34.85 million, and RMB 52.29 million [4][4]. - **Juzhi Technology Development Co., Ltd.**: Submitted an application on July 23, focusing on baby monitoring products. Revenue for 2022 to 2024 was approximately RMB 1.90 billion, RMB 3.48 billion, and RMB 4.62 billion respectively, with net profits of RMB 34.82 million, RMB 63.36 million, and RMB 94.69 million [5][6]. - **Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd.**: Submitted an application on July 24, specializing in vaccines. Revenue for 2023 to 2025 was approximately RMB 52.17 million, RMB 260 million, and RMB 410,000 respectively, with net losses of RMB 425 million, RMB 259 million, and RMB 87.32 million [7][7]. - **Fujian Lemo IoT Technology Co., Ltd.**: Submitted an application on July 25, a leader in smart massage services in mainland China, with a market share of 33.9% to 42.9% from 2022 to 2024. Revenue for 2022 to 2024 was approximately RMB 3.30 billion, RMB 5.87 billion, and RMB 7.98 billion respectively, with net profits of RMB 6.48 million, RMB 87.34 million, and RMB 85.81 million [8][8]. - **Anhui Jinyan High Clay New Materials Co., Ltd.**: Submitted an application on July 25, specializing in kaolin materials with a market share of 19.1%. Revenue for 2022 to 2024 was approximately RMB 1.90 billion, RMB 2.05 billion, and RMB 2.67 billion respectively, with net profits of RMB 24.42 million, RMB 43.61 million, and RMB 52.60 million [9][9]. - **Shandong Shengruan Technology Co., Ltd.**: Submitted an application on July 26, providing digital solutions for energy and manufacturing sectors. Revenue for 2022 to 2024 was approximately RMB 3.91 billion, RMB 5.02 billion, and RMB 5.25 billion respectively, with net profits of RMB 37.60 million, RMB 53.70 million, and RMB 59.30 million [10][10]. - **AIWB Inc.**: Submitted an application on July 25, focusing on smart building solutions in Texas. Revenue for 2022 to 2024 was approximately USD 103 million, USD 121 million, and USD 105 million respectively, with net losses of USD 347,000, USD 620,000, and USD 531,000 [11][11]. Company Hearing and IPO - **Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd.**: Passed the hearing on July 27, focusing on innovative vaccines with two core products. Revenue for 2023 to 2025 was approximately RMB 52.17 million, RMB 260 million, and RMB 410,000 respectively, with net losses of RMB 425 million, RMB 259 million, and RMB 87.32 million [12][12]. - **Vili Zhibo-B (09887.HK)**: Launched an IPO from July 17 to July 22, with a subscription rate of 3494.78 times in the public offering. The stock began trading on July 25 at HKD 67.10, a 91.71% increase [13][14].

Group 1 - The China Securities Regulatory Commission (CSRC) has requested Saintong Special Medical to provide supplementary explanations regarding the legality and compliance of its historical equity changes and the status of shares held by shareholders participating in the "full circulation" [1][3] - Saintong Special Medical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor [1] - The company is recognized as a leading provider of special medical foods in China, holding the top position among domestic brands in the special medical food market with a market share of 6.3% as of 2024 [3] Group 2 - The CSRC has mandated a legal opinion on the compliance of the company's equity incentive plan post-listing and whether there are any issues of interest transfer [1] - The company must clarify its operational scope related to the sale of health food products and confirm whether it has obtained the necessary qualifications and licenses [1] - Saintong Special Medical is also the leading domestic brand in the infant special medical food market, with a market share of 9.5% [3]

Core Viewpoint - The company, Daxing Technology, is making a second attempt to go public in Hong Kong, having submitted its IPO application again after a previous attempt earlier this year. The company plans to issue no more than 9.1 million overseas ordinary shares [2]. Financial Performance - Daxing Technology's revenue and net profit for the years 2022 to 2024 and the first four months of 2025 are reported as follows: - Revenue: 254 million, 300 million, 451 million, and 185 million respectively - Net Profit: approximately 31.43 million, 34.85 million, 52.29 million, and 21.52 million respectively [4][5]. - The company has experienced rapid growth, with both revenue and net profit growth rates exceeding 50% in 2024. Daxing Technology holds a 26.3% market share by retail volume and a 36.5% market share by retail value in the folding bicycle industry in mainland China [5]. Production Capacity and Challenges - Daxing Technology has faced significant challenges regarding its production capacity, with its factory in Huizhou, Guangdong, operating at over 100% capacity utilization, reaching 114.1% in the first four months of 2025 [6][9]. - The company relies heavily on third-party OEM suppliers, with the number of bicycles produced by OEMs increasing from 29.5% in 2022 to 65.5% in the first four months of 2025. This reliance has led to rising production costs, with outsourced production costs accounting for nearly half of the sales costs in 2024 [8]. Dividend Distribution and Financial Obligations - Daxing Technology has made substantial dividend payments, totaling over 60 million, with most of the dividends benefiting the major shareholder, Han Dewei, who holds approximately 90.16% of the company's shares [10][13]. - Despite these dividends, the company has accumulated unpaid social insurance contributions amounting to 6.4 million since 2022, raising concerns about its financial management and obligations to employees [14].

Group 1 - The core point of the article highlights the significant discrepancies in share transfer prices of Yifei Technology prior to its IPO application, raising questions about the fairness and transparency of these transactions [2][3][7] - Yifei Technology's major shareholder, Zhang Sai, controls approximately 25.07% of the voting rights, making him the largest shareholder as of the signing date of the prospectus [3] - The company has experienced substantial revenue growth over the reporting period, with revenues of 162.21 million yuan, 201.17 million yuan, and 268.01 million yuan from 2022 to 2024, respectively [8] Group 2 - Despite the revenue growth, Yifei Technology has faced continuous losses, totaling 239.65 million yuan over three years, with annual losses of 57.55 million yuan, 110.61 million yuan, and 71.50 million yuan [8][9] - The company's operating cash flow has consistently been negative, with a total outflow of approximately 200 million yuan over three years, indicating a failure to achieve self-sustaining cash generation [10] - The company’s cash and cash equivalents were reported at approximately 22.89 million yuan by the end of 2024, while facing significant short-term debt pressures due to rising bank borrowings [10]

Core Insights - The event "2025 Hong Kong IPO Salon" focused on the latest trends, policy benefits, and compliance points in the Hong Kong capital market for IPOs, aiming to help companies seize opportunities and efficiently connect with capital [1][15] Market Trends - Hong Kong's IPO market achieved a fundraising amount of $13.9 billion in the first half of 2025, accounting for 25% of the global total, with four out of the top ten IPOs taking place on the Hong Kong Stock Exchange [5] - There is a growing trend of A-share companies, such as CATL and Hansoh Pharmaceutical, pursuing dual listings in Hong Kong, with 197 companies already registered for this [5] - Future trends in the Hong Kong IPO market are expected to include the return of Chinese concept stocks, green energy initiatives, A+H share collaborations, and internationalization [5] Listing Pathways - The conditions and requirements for listing on the Hong Kong Stock Exchange were discussed, highlighting the reasons for its preference among A-share and Chinese concept companies due to regulatory collaboration and policy relaxation [7] - The approval process has been streamlined, with initiatives like the "Five Measures to Benefit Hong Kong" and "Tech Enterprise Fast Track" reducing the approval timeline to 30 working days [7] - Key aspects of the listing process include the importance of independent transactions and the composition of the listing project team [7] ESG Impact - The Hong Kong Stock Exchange is enhancing ESG disclosure rules, with new policies supporting green technology companies, which can significantly lower financing costs and improve valuations [10] - From 2025, large issuers will be required to disclose according to new climate guidelines, and companies with clear funding purposes directed towards green energy and smart manufacturing will be favored by regulators and investors [10] Practical Engagement - The event included a "project matching and on-site diagnosis" area where companies looking to list in Hong Kong could consult with brokers, lawyers, and accountants for tailored advice [11] - A comprehensive overview of the China Securities Regulatory Commission's filing process for companies seeking to list in Hong Kong was provided, emphasizing the importance of early planning to avoid rework [12] Conclusion - The "2025 Hong Kong IPO Salon" successfully created a platform for efficient dialogue between capital, professional institutions, and enterprises, facilitating a better understanding of the latest policies and practical pathways for companies in the Guangdong-Hong Kong-Macao Greater Bay Area [14][15]